Synmedix is a biotechnology company focused on enhancing antibiotics to combat antibiotic resistance. Founded on McMaster University technology, its novel platform improves the efficacy and spectrum of antibiotics, enabling treatment of multidrug-resistant infections. Synmedix’s lead product targets infections in diabetic foot ulcers, with a mission to deliver new, effective therapies while addressing clinical gaps and avoiding resistance, all with equitable economics.